Neogen Earnings Call Transcripts
Fiscal Year 2026
-
Core food safety growth and improved margins offset animal safety supply chain headwinds, leading to raised FY26 revenue guidance. Petrifilm transition and genomics divestiture support future margin expansion and debt reduction.
-
A new leadership team is driving a turnaround with a three-stage strategy focused on stabilization, growth, and innovation. The company is refocusing its portfolio, investing in R&D, and expects to divest its genomics division by year-end. Q2 results exceeded expectations, supporting cautious optimism for sustained recovery.
-
Q2 saw a return to positive core growth and significant margin improvement, prompting raised full-year guidance. Food safety led segment growth, while cost actions and divestitures improved profitability and cash flow. Macroeconomic headwinds persist, but operational execution and leadership changes are driving transformation.
-
Q1 revenue was $209M, up 0.3% year-over-year, with adjusted EBITDA margin at 17%. Cost reductions and operational improvements are underway, with full-year guidance reaffirmed and sequential margin improvement expected as process enhancements take effect.
Fiscal Year 2025
-
Q4 revenue declined year-over-year amid soft end markets, inventory and production challenges, and tariff headwinds. Guidance for fiscal 2026 anticipates modest revenue growth, improved margins in the second half, and positive free cash flow, with continued focus on operational improvements and divestitures.
-
Food safety testing now dominates the portfolio following a major acquisition, with two divestitures in progress to streamline operations and reduce debt. Market growth has slowed due to inflation and trade uncertainty, but operational improvements and integration milestones are expected to drive recovery and margin normalization over the next year.
-
Third quarter results missed expectations due to macro uncertainty, softening end markets, and tariff impacts. Food safety core revenue grew 7% excluding sample collection, while animal safety and genomics faced headwinds. Full-year guidance was lowered, with cost actions and portfolio focus underway.
-
The presentation highlighted strong secular tailwinds in food safety, ongoing regulatory changes, and a broadening product portfolio following the 3M integration. Despite recent market headwinds and a reduction in revenue guidance, operational improvements and portfolio optimization are positioning the business for renewed growth and margin expansion.
-
Q2 saw sequential improvements in revenue, margin, and cash flow, with core revenue up 3.5% year-over-year despite FX headwinds. Guidance was reduced due to FX, genomics restructuring, and sample collection delays, but margin improvement is expected in the second half.
-
Q1 revenue declined slightly year-over-year, with Food Safety showing core growth but Animal Safety and Genomics segments facing headwinds. Guidance for fiscal 2025 is maintained, with expectations for stronger performance in the second half and ongoing focus on integration, efficiency, and international expansion.
Fiscal Year 2024
-
Q2 revenue reached $230 million with sequential core growth improvement and margin initiatives set for impact in the second half. Integration of the 3M food safety business is nearly complete, international expansion is accelerating, and operational recovery is driving renewed market share gains.
-
First quarter results met expectations, with operational challenges from 2024 now resolved and integration of the 3M business nearly complete. Growth is expected to be driven by international expansion, innovation, and margin improvement, with positive free cash flow anticipated in 2025.
-
Q4 saw modest core revenue growth and strong innovation, despite headwinds from distribution inefficiencies and soft end markets. Integration milestones were achieved, and FY25 guidance anticipates margin expansion, lower CapEx, and positive free cash flow.
-
The company is advancing food safety and animal health globally, leveraging innovation in diagnostics, data analytics, and genomics. Integration of recent acquisitions is nearly complete, with new manufacturing capacity and strong financial outlook supporting growth in under-penetrated markets.